🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Resectable Pancreatic Adenocarcinoma

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06673017Phase 19 sites📍 Newport Beach📍 Miami📍 Detroit PanTher Therapeutics · Tests: PTM-101 Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer NCT06782932Phase 1, Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: AGEN2373, Balstilimab, Cyclophosphamide, GVAX, AGEN2373 (RP2D) Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC) NCT04926467Phase 21 site📍 Dallas Baylor Research Institute · Tests: Anakinra Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) NCT06384560Phase 1, Phase 24 sites📍 Amsterdam📍 Maastricht📍 Nieuwegein Amsterdam UMC, location VUmc · Tests: Pembrolizumab, Folfirinox, SABR Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma NCT05688215Phase 1, Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biospecimen Collection, Computed Tomography, Core Biopsy, Fluorouracil, Irinotecan Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1 NCT06649474NA1 site📍 Clermont-Ferrand University Hospital, Clermont-Ferrand · Tests: assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma NCT05825066Phase 22 sites📍 Charlotte📍 Winston-Salem Wake Forest University Health Sciences · Tests: Nab paclitaxel, Gemcitabine, Radiological Assessments, mFOLFIRINOX Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer NCT06065891NA6 sites📍 Odense📍 Gothenburg📍 Linköping Jon Unosson · Tests: PALN resection A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer NCT07898683Phase 11 site📍 Obninsk National Medical Research Radiological Centre of the Minist… · Tests: Transarterial Radioembolization A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer NCT07481383Phase 12 sites📍 Ann Arbor📍 Morgantown Continuity Biosciences, LLC · Tests: ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003) A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer NCT07671339Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: ELI-002 7P, Tislelizumab, mFOLFIRINOX Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy NCT07022015NA1 site📍 Minya Minia University · Tests: pancreaticoduodenectomy procedure Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma NCT05518903Phase 21 site📍 Rochester Mayo Clinic · Tests: Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula NCT05116072Phase 1, Phase 21 site📍 Lille University Hospital, Lille · Tests: total pancreatectomy, intraportal islet autotransplantation Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017Phase 111 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles Nammi Therapeutics Inc · Tests: QXL138AM Injection every 2 weeks by IV Infusion Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma NCT04998552NA1 site📍 Pennington Capital Health System, Inc · Tests: Cyberknife Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) NCT07252232Phase 386 sites📍 Birmingham📍 Phoenix📍 Scottsdale Revolution Medicines, Inc. · Tests: daraxonrasib PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer NCT05524090n/a1 site📍 Amsterdam Academisch Medisch Centrum - Universiteit van Amsterdam (AM… · Tests: Implementation - International best-practice care Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer NCT03977233Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Oxaliplatin, Leucovorin, Irinotecan Hydrochloride, 5-FU Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer NCT07645651Phase 11 site📍 Seattle University of Washington · Tests: Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy, Biospecimen Collection PULSAR in Systemic Therapy for Pancreatic Cancer NCT07269626Phase 21 site📍 Seoul Samsung Medical Center · Tests: Personalized Ultrafractionated Adaptive Radiotherapy APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation NCT04858334Phase 2456 sites📍 Anchorage📍 Anchorage📍 Anchorage National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration Intravital Microscopy in Human Solid Tumors NCT03823144NA1 site📍 Jacksonville Mayo Clinic · Tests: Diagnostic Microscopy, Fluorescein Sodium Injection Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma NCT06141031Phase 12 sites📍 Aurora📍 St Louis Washington University School of Medicine · Tests: TTI-101, Stereotactic body radiation therapy Targeted Pathway Inhibition in Patients With Pancreatic Cancer NCT04005690EARLY Phase 11 site📍 Portland OHSU Knight Cancer Institute · Tests: Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer NCT04969731Phase 31 site📍 Seoul GC Cell Corporation · Tests: Immuncell-LC, Gemcitabine Durvalumab and Oleclumab in Resectable PDAC NCT06060405Phase 21 site📍 Toronto University Health Network, Toronto · Tests: Durvalumab, Oleclumab A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) NCT05851924Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: NALIRIFOX, AD-XRT and Capecitabine Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC NCT06714604Phase 31 site📍 Gothenburg Sahlgrenska University Hospital · Tests: FOLFIRINOX or gemcitabine-nab-paclitaxel, FOLFIRINOX or gemcitabine-nab-paclitaxel Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer NCT03492671Phase 21 site📍 Loma Linda Loma Linda University · Tests: Gemcitabine 1000 mg, nab-paclitaxel, Stereotactic Body Radiation Therapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy